MGMT and central nervous system cancer: The results of this study demonstrate that TERT promoter mutations–specifically, −124 C>T and −146 C>T–can be used alone or possible in conjunction with other mutations, such as the isocitrate dehydrogenase 1 mutation and MGMT methylation, as a prognostic biomarker and indicator of pathological grade of gliomas.